Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 10/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 10/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 10/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23084436 | 0.85 | PKM (0.32) | KMT2APKM | |
| SCHEMBL6659132 | 0.82 | ALDH1A3 (0.37) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21048901 | 0.74 | PTGS2 (0.36) | KMT2APER2CRY1CRY2EPAS1 | |
| SCHEMBL2369020 | 0.71 | KMT2A (0.49) | KMT2AEPAS1PKMPTGS2PTGS1 | |
| SCHEMBL29545876 | 0.71 | KMT2A (0.49) | KMT2AEPAS1PKMPTGS2PTGS1 | |
| SCHEMBL124345 | 0.70 | ALDH1A1 (0.33) | KMT2APER2 | |
| SCHEMBL16914845 | 0.70 | CES2 (0.38) | PER2CRY1CRY2PSEN1PSEN2 | |
| SCHEMBL7046878 | 0.69 | PSEN1 (0.35) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23084391 | 0.69 | PSEN1 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29757454 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244615-B1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | US | disclosed |
| EP-1244615-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | DDT, PFAS, DAO | KMT2A 841/4885PER2 4072/4885CRY1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.